Literature DB >> 22503355

Prevalence of metabolic syndrome in patients with schizophrenia in India.

Sandeep Grover1, Munish Aggarwal, Alakananda Dutt, Subho Chakrabarti, Ajit Avasthi, Parmanand Kulhara, Mansi Somaiya, Nidhi Malhotra, Nidhi Chauhan.   

Abstract

Prevalence of metabolic syndrome (MS) was estimated in 227 patients with schizophrenia. A total of 43.6% of patients fulfilled International Diabetes Federation (IDF) criteria and 44.5% met modified National Cholesterol Education Program Adult Treatment Panel-III (NCEP ATP- III) criteria of MS. Increased waist circumference was the most common abnormality (64.8%) and high glucose level was the least common (15.9%). In regression analysis, age more than 35 years (OR-3.37), female gender (odds ratios (OR-1.81)), urban locality (OR-2.08), being employed (OR-2.12) and BMI more than 25 (OR-5.64) emerged as significant predictors of MS.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 22503355     DOI： 10.1016/j.psychres.2012.03.043

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN： 0165-1781            Impact factor:   3.222


  8 in total

1.  Metabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders: A 24-week prospective study.

Authors:  Praveen Rikhari; Ashutosh Kumar; Prabhat Agrawal; Harendra Kumar
Journal:  J Family Med Prim Care       Date:  2022-05-14

2.  The prevalence and clinical correlates of metabolic syndrome and cardiometabolic alterations in 430 drug-naive patients in their first episode of schizophrenia.

Authors:  Xiaoe Lang; Qinqin Liu; Hanliu Fang; Yongjie Zhou; Mattew T Forster; Zezhi Li; Xiangyang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2021-09-29       Impact factor: 4.530

3.  Metabolic syndrome and 10-year risk of cardiovascular events among schizophrenia inpatients treated with antipsychotics.

Authors:  Shadi Naderyan Fe'li; Seyed Mojtaba Yassini Ardekani; Hosein Fallahzadeh; Ali Dehghani
Journal:  Med J Islam Repub Iran       Date:  2019-09-16

4.  Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review.

Authors:  Marius H Sneller; Nini de Boer; Sophie Everaars; Max Schuurmans; Sinan Guloksuz; Wiepke Cahn; Jurjen J Luykx
Journal:  Front Psychiatry       Date:  2021-03-29       Impact factor: 4.157

5.  Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia.

Authors:  Feyissa Challa; Tigist Getahun; Meron Sileshi; Zeleke Geto; Teshome S Kelkile; Sintayehu Gurmessa; Girmay Medhin; Miraf Mesfin; Melkam Alemayehu; Tigist Shumet; Anwar Mulugeta; Desalegn Bekele; Christina P C Borba; Claire E Oppenheim; David C Henderson; Abebaw Fekadu; Anna Carobene; Solomon Teferra
Journal:  BMC Psychiatry       Date:  2021-12-11       Impact factor: 3.630

6.  Metabolic syndrome following a first episode of psychosis: results of a 1-year longitudinal study conducted in metropolitan Lisbon, Portugal.

Authors:  Ricardo Coentre; Pedro Levy; Carlos Góis; Maria Luísa Figueira
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

Review 7.  Metabolic syndrome in schizophrenia.

Authors:  Nidhi Malhotra; Sandeep Grover; Subho Chakrabarti; Parmanand Kulhara
Journal:  Indian J Psychol Med       Date:  2013-07

8.  Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region.

Authors:  Tak Lam Lo; Matthew Warden; Yanling He; Tianmei Si; Seshadri Kalyanasundaram; Manickam Thirunavukarasu; Nurmiati Amir; Ahmad Hatim; Tomas Bautista; Cheng Lee; Robin Emsley; Jose Olivares; Yen Kuang Yang; Ronnachai Kongsakon; David Castle
Journal:  Asia Pac Psychiatry       Date:  2016-06       Impact factor: 2.538
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.